Recent News

• 08.10.2026 - Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
• 08.03.2026 - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 07.30.2026 - Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
• 07.30.2026 - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
• 07.01.2026 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2026 - Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
• 06.02.2026 - Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
• 06.02.2026 - Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
• 06.01.2026 - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.01.2026 - Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Recent Filings

• 07.31.2026 - 8-K Current report
• 07.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.28.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.17.2026 - 8-K Current report
• 06.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.28.2026 - 8-K Current report
• 05.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities